Non Interventional Longitudinal Study To Assess The Acceptability And The Satisfaction Of Patients With Haemophilia A Treated Both On Demand And On Prophylaxis With A New Factor Viii Delivery System Fusengo

Trial Profile

Non Interventional Longitudinal Study To Assess The Acceptability And The Satisfaction Of Patients With Haemophilia A Treated Both On Demand And On Prophylaxis With A New Factor Viii Delivery System Fusengo

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Mar 2017

At a glance

  • Drugs Moroctocog alfa (Primary)
  • Indications Haemophilia A
  • Focus Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 21 Feb 2017 Status changed from active, no longer recruiting to completed.
    • 29 Nov 2016 Status changed from recruiting to active, no longer recruiting.
    • 02 Mar 2016 Planned number of patients changed from 200 to 120 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top